Sign in

    Kelly Close • Close Concerns

    Kelly Close is the President and Founder of Close Concerns, Inc., specializing in healthcare analysis with an exclusive focus on diabetes, obesity, and digital health. She has overseen research coverage on more than 60 public and private companies in the diabetes sector, delivering extensive market analysis through widely circulated newsletters such as Diabetes Close Up and Closer Look, which reach thousands of industry professionals and patients globally. With a career starting as an analyst at Goldman Sachs, followed by consulting at McKinsey & Company and then founding Close Concerns in 2002, Close is also the Editor-in-Chief of diaTribe, reaching millions annually. An alumna of Amherst College and Harvard Business School, Close is recognized for her contributions by organizations like the American Diabetes Association and serves on several diabetes-related boards.

    Kelly Close's questions to Beta Bionics Inc (BBNX) leadership

    Kelly Close's questions to Beta Bionics Inc (BBNX) leadership • Q1 2025

    Question

    Kelly Close asked for perspective on the Type 2 market opportunity, specifically whether the greater potential lies with patients on basal insulin who need more help or those on MDI who could benefit from a simpler therapy.

    Answer

    CEO Sean Saint stated that while both are opportunities, the most natural entry point for pump therapy in the Type 2 population is with patients already on intensive insulin therapy (MDI). He reasoned that their management is very similar to Type 1 diabetes, and they stand to benefit significantly from the iLet's simplicity compared to the challenges of MDI.

    Ask Fintool Equity Research AI